RCSI research suggests that anti-rejection medications for multiple kidney transplants increase the risk of skin cancer
A study led by researchers at RCSI has analysed the pattern of skin cancer rates in kidney transplant patients, which suggests the increased risk is related to the anti-rejection medications.
The research is published in JAMA Dermatology and was a collaboration between the National Cancer Registry Ireland and the National Kidney Transplant Service in Beaumont Hospital.
Patients who receive a kidney transplant are at increased risk of cancer, in particular skin cancer. The study found that this skin cancer risk falls when the transplant fails and the patients return to dialysis but rises again when they receive another transplant. However, the rate of skin cancer is still higher in patients with failed transplants than pre-transplant patients on dialysis.
Due to this pattern of skin cancer rates, the data suggests that the cancer risk is related to the stopping and starting of anti-rejection medications.
“In recipients of multiple kidney transplants, the incidence of nonmelanoma skin cancer fell during periods defined by transplant failure, but there was still an elevated risk. The incidence of cancer overall highlights the need for continued cancer surveillance during graft failure,” said the study’s lead author Dr Donal Sexton, Department of Nephrology and Kidney Transplantation, Beaumont Hospital, RCSI.
The study analysed the rates of cancer in 3,821 individual deceased and living kidney transplant recipients. Of the patients analysed, 3,215 recipients had one transplant, 522 recipients a second; and 84 recipients had three kidney transplants.
During the patient’s first kidney transplant, the rate of skin cancer rose 15 times higher than before the procedure. That skin cancer rate fell by half when the transplant failed and the patient returned to dialysis; however, the rate was still seven times higher than the pre-transplant patient’s rate. When they received a second transplant, the rate of skin cancer rose again to 12.8 times more than pre-transplant rate.
“Our study has provided a comprehensive analysis of cancer risk over multiple kidney transplants in the same individuals. However, the retrospective nature of the analysis makes it difficult to capture the effect of the lag between exposure, cancer development, presentation, and diagnosis, and which may vary by treatment period,“ said Professor Peter Conlon, Associate Professor of Medicine at RCSI.
RCSI is ranked among the top 250 (top 2%) of universities worldwide in the Times Higher Education World University Rankings (2019) and its research is ranked first in Ireland for citations. It is an international not-for-profit health sciences institution, with its headquarters in Dublin, focused on education and research to drive improvements in human health worldwide. RCSI has been awarded Athena Swan Bronze accreditation for positive gender practice in higher education.